However, a negative result on these tests is not sufficiently precise to exclude a clinical benefit from PARP inhibitors among BRCA wild‐type ovarian cancers in either the treatment or maintenance setting.11, 12, 85 However, more clinical trials are warranted to further investigate the role of these HRD biomarkers in predicting benefits from PARP inhibitors. Here, PARP1 is linked to ovarian carcinoma.